Proto Script Pharmaceutical Stock

Proto Script Pharmaceutical EBITDA per Share

EBITDA per Share of Proto Script Pharmaceutical (PSCR) as of Jul 25, 2026.

EBITDA per Share

-0.00USD

YoY

-13.21%

Last updated:

EBITDA per Share of Proto Script Pharmaceutical is 2026 -0.00 USD. EBITDA per Share of Proto Script Pharmaceutical was 2025 -0.00 USD. It decreases by -13.21% higher compared to the previous year.
Access this data via the Eulerpool API

Proto Script Pharmaceutical Stock analysis

What does Proto Script Pharmaceutical do? Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide. Proto Script Pharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proto Script Pharmaceutical stock

On Eulerpool you can find the complete historical development of EBITDA per Share Proto Script Pharmaceutical since 2006 – with annual values, charts, and detailed analysis.

Access this data via the Eulerpool API

Income Statement — Proto Script Pharmaceutical

All Key Metrics — Proto Script Pharmaceutical